<p>Bradley &amp; Co. Private Wealth Management LLC 在最近向美国证券交易委员会提交的 13F 文件中披露，在第四季度收购了 CareDx, Inc (NASDAQ:CDNA - 免费报告) 的新股份。该公司收购了 12,587 股，价值约 269,000 美元。</p>
<p>其他一些大型投资者最近也调整了他们对 CDNA 的持股。Quarry LP 在第三季度以约 27,000 美元的价格购买了 CareDx 的新股份。Harvest Fund Management Co. Ltd 在第三季度以 52,000 美元的价格购买了 CareDx 的新头寸。KBC Group NV 在第三季度以 99,000 美元的价格购买了 CareDx 的新头寸。Quest Partners LLC 在第三季度将其在 CareDx 的持股增加了 37.8%。Quest Partners LLC 目前拥有 5,611 股，价值 175,000 美元，在上个季度又收购了 1,540 股。最后，Creative Planning 在第三季度以 204,000 美元的价格购买了 CareDx 的新股份。</p>
<h2>CareDx 股票下跌 2.2%</h2>
<p>CDNA 股票周三开盘价为 20.89 美元。CareDx, Inc 的 12 个月最低价为 7.42 美元，最高价为 34.84 美元。该股票的市值为 11.2 亿美元，市盈率为 -7.74，贝塔系数为 1.87。该公司的 50 日简单移动平均线为 22.64 美元，200 日简单移动平均线为 25.32 美元。</p>
<h2>华尔街分析师观点</h2>
<p>几家券商最近对 CDNA 发布了报告。富国银行将 CareDx 的评级从 “减持” 上调至 “持平”，并在 1 月 15 日的报告中将其目标价从 28.00 美元下调至 24.00 美元。HC Wainwright 在 1 月 14 日的报告中重申了 “中性” 评级，并设定了 26.00 美元的目标价。BTIG Research 在 11 月 5 日的研究报告中将 CareDx 的目标价从 40.00 美元下调至 35.00 美元，并对该股票给予 “买入” 评级。最后，StockNews.com 在周三的研究报告中将 CareDx 的评级从 “持有” 上调至 “买入”。三位股票研究分析师对该股票给予了持有评级，五位分析师给予了买入评级。根据 MarketBeat 的数据，CareDx 目前的平均评级为 “适度买入”，平均目标价为 28.33 美元。</p>
<p><strong>获取我们最新的 CareDx 股票分析</strong></p>
<h2>CareDx 公司简介</h2>
<p>(免费报告)</p>
<p>CareDx, Inc 从事为美国及国际的移植患者和护理人员开发、发现和商业化诊断解决方案。它还提供 AlloSure Kidney，一种用于肾移植患者的供体衍生无细胞 DNA (dd-cfDNA) 解决方案；AlloMap Heart，一种用于心脏移植患者的基因表达解决方案；AlloSure Heart，一种用于心脏移植患者的 dd-cfDNA 解决方案；以及 AlloSure Lung，一种用于肺移植患者的 dd-cfDNA 解决方案。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 CareDx 更好</li>
<li>最佳航空航天股票投资</li>
<li>Nebius 财报后下滑：长期买入机会？</li>
<li>WallStreetBets 是什么，目标股票有哪些？</li>
<li>NVIDIA 股票：科技动荡时期的市场晴雨表</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>Palantir 股票接近熊市区域 - 原因及下一步？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CareDx 吗？</h2>
<p>在你考虑 CareDx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 CareDx 并不在名单上。</p>
<p>虽然 CareDx 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

CDNA

<p>Bradley & Co. Private Wealth Management LLC 在 CareDx, Inc (NASDAQ:CDNA) 中获得了新的股份，在第四季度购买了价值约 269,000 美元的 12,587 股。其他投资者也增加了对 CareDx 的持股。该股票目前下跌 2.2%，市值为 11.2 亿美元，市盈率为 -7.74。分析师对该股票的评级不一，平均评级为 “适度买入”，目标价格为 28.33 美元</p>

<p>Bradley &amp; Co. Private Wealth Management LLC acquired a new stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,587 shares of the company's stock, valued at approximately $269,000.</p>
<div class="lb-trans"><p>Bradley &amp; Co. Private Wealth Management LLC 在最近向美国证券交易委员会提交的 13F 文件中披露，在第四季度收购了 CareDx, Inc (NASDAQ:CDNA - 免费报告) 的新股份。该公司收购了 12,587 股，价值约 269,000 美元。</p>
</div><p>A number of other large investors also recently modified their holdings of CDNA. Quarry LP purchased a new stake in CareDx during the 3rd quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new position in CareDx during the third quarter valued at $52,000. KBC Group NV purchased a new position in CareDx during the third quarter valued at $99,000. Quest Partners LLC increased its holdings in CareDx by 37.8% in the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company's stock valued at $175,000 after acquiring an additional 1,540 shares during the last quarter. Finally, Creative Planning purchased a new stake in CareDx in the 3rd quarter worth $204,000.</p>
<div class="lb-trans"><p>其他一些大型投资者最近也调整了他们对 CDNA 的持股。Quarry LP 在第三季度以约 27,000 美元的价格购买了 CareDx 的新股份。Harvest Fund Management Co. Ltd 在第三季度以 52,000 美元的价格购买了 CareDx 的新头寸。KBC Group NV 在第三季度以 99,000 美元的价格购买了 CareDx 的新头寸。Quest Partners LLC 在第三季度将其在 CareDx 的持股增加了 37.8%。Quest Partners LLC 目前拥有 5,611 股，价值 175,000 美元，在上个季度又收购了 1,540 股。最后，Creative Planning 在第三季度以 204,000 美元的价格购买了 CareDx 的新股份。</p>
</div><h2>CareDx Stock Down 2.2 %</h2>
<div class="lb-trans"><h2>CareDx 股票下跌 2.2%</h2>
</div><p>CDNA stock opened at $20.89 on Wednesday. CareDx, Inc has a twelve month low of $7.42 and a twelve month high of $34.84. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -7.74 and a beta of 1.87. The firm's fifty day simple moving average is $22.64 and its two-hundred day simple moving average is $25.32.</p>
<div class="lb-trans"><p>CDNA 股票周三开盘价为 20.89 美元。CareDx, Inc 的 12 个月最低价为 7.42 美元，最高价为 34.84 美元。该股票的市值为 11.2 亿美元，市盈率为 -7.74，贝塔系数为 1.87。该公司的 50 日简单移动平均线为 22.64 美元，200 日简单移动平均线为 25.32 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several brokerages have recently issued reports on CDNA. Wells Fargo &amp; Company raised CareDx from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and reduced their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. HC Wainwright reaffirmed a &#34;neutral&#34; rating and set a $26.00 price objective on shares of CareDx in a report on Tuesday, January 14th. BTIG Research reduced their price target on shares of CareDx from $40.00 to $35.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of CareDx from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, CareDx presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $28.33.</p>
<div class="lb-trans"><p>几家券商最近对 CDNA 发布了报告。富国银行将 CareDx 的评级从 “减持” 上调至 “持平”，并在 1 月 15 日的报告中将其目标价从 28.00 美元下调至 24.00 美元。HC Wainwright 在 1 月 14 日的报告中重申了 “中性” 评级，并设定了 26.00 美元的目标价。BTIG Research 在 11 月 5 日的研究报告中将 CareDx 的目标价从 40.00 美元下调至 35.00 美元，并对该股票给予 “买入” 评级。最后，StockNews.com 在周三的研究报告中将 CareDx 的评级从 “持有” 上调至 “买入”。三位股票研究分析师对该股票给予了持有评级，五位分析师给予了买入评级。根据 MarketBeat 的数据，CareDx 目前的平均评级为 “适度买入”，平均目标价为 28.33 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on CareDx</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 CareDx 股票分析</strong></p>
</div><h2>CareDx Company Profile</h2>
<div class="lb-trans"><h2>CareDx 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.</p>
<div class="lb-trans"><p>CareDx, Inc 从事为美国及国际的移植患者和护理人员开发、发现和商业化诊断解决方案。它还提供 AlloSure Kidney，一种用于肾移植患者的供体衍生无细胞 DNA (dd-cfDNA) 解决方案；AlloMap Heart，一种用于心脏移植患者的基因表达解决方案；AlloSure Heart，一种用于心脏移植患者的 dd-cfDNA 解决方案；以及 AlloSure Lung，一种用于肺移植患者的 dd-cfDNA 解决方案。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than CareDx</li>
<li>Best Aerospace Stocks Investing</li>
<li>Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Palantir Stock Nears Bear Market Territory - Why and What’s Next?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 CareDx 更好</li>
<li>最佳航空航天股票投资</li>
<li>Nebius 财报后下滑：长期买入机会？</li>
<li>WallStreetBets 是什么，目标股票有哪些？</li>
<li>NVIDIA 股票：科技动荡时期的市场晴雨表</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>Palantir 股票接近熊市区域 - 原因及下一步？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CDNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CareDx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CareDx 吗？</h2>
</div><p>Before you consider CareDx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 CareDx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 CareDx 并不在名单上。</p>
</div><p>While CareDx currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CareDx 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Bradley & Co. Private Wealth Management LLC 对 CareDx, Inc (NASDAQ:CDNA) 进行了新投资